Gilead Sciences Inc. (NASDAQ:GILD) shares slipped in Tuesday’s extended trading after the company released its fourth-quarter earnings report with weak fiscal 2026 guidance.
Here’s a look at the key figures from the quarter.
- GILD stock is moving. Watch the price action here.
The Details: Gilead reported quarterly earnings of $1.86 per share, which beat the consensus estimate of $1.81, according to data from Benzinga Pro.
Quarterly revenue came in at $7.93 billion, which beat the Street estimate of $7.69 billion.
The company reports the following fourth quarter metrics:
- Liver Disease portfolio sales increased 17% to $844 million in the fourth quarter of 2025 compared to the same period in 2024, primarily driven by higher demand for Livdelzi (seladelpar).
- HIV product sales increased 6% to $5.8 billion in the fourth quarter of 2025 compared to the same period in 2024, primarily driven by higher demand for HIV prevention and treatment.
- Cell Therapy product sales decreased 6% to $458 million in the fourth quarter of 2025 compared to the same period in 2024, reflecting ongoing competitive headwinds.
“Our fourth quarter and full-year results close out a very strong year for Gilead overall, including the successful U.S. launch of Yeztugo, the world’s first twice-yearly HIV prevention therapy, and continued growth for Biktarvy and Descovy,” said CEO Daniel O’Day.
Outlook: Gilead expects fiscal 2026 adjusted EPS of $8.45 to $8.85, versus the $8.74 analyst estimate, and revenue in a range of $29.6 billion to $30 billion, versus the $30.22 billion estimate.
GILD Stock Price: According to data from Benzinga Pro, Gilead stock dropped 2.87% to $143 in Tuesday’s extended trading.
Photo: Sundry Photography / Shutterstock
Recent Comments